China Keytruda market comprehensive commercial assessment — the multi-indication pembrolizumab revenue across oncology from NRDL-covered and out-of-pocket access in China's healthcare system — reflects both the global commercial importance of pembrolizumab as the world's best-selling drug and the unique commercial dynamics constraining and shaping its Chinese market performance,...